Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC

Locally Advanced Lung Carcinoma Clinical Trial

Official title:
Fraction Dose Escalation of Hypofractionated Radiotherapy With Concurrent Chemotherapy and Subsequent Consolidation Immunotherapy in Locally Advanced Non-small Cell Lung Cancer: a Phase 1 Study

Status Completed

Clinical Trial Summary

This Phase 1 trial aimed to determine the maximum tolerated fraction dose (MTD) of hypofractionated radiotherapy (hypo-RT) combined with concurrent chemotherapy and subsequent consolidation immune checkpoint inhibitors (cICI) for patients with locally advanced non-small cell lung cancer (LA-NSCLC).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04951063
Study type	Interventional
Source	Sun Yat-sen University
Contact
Status	Completed
Phase	Phase 1
Start date	June 1, 2021
Completion date	September 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04726358` - ProCaLung: Project on Cancer of the Lung
Recruiting	`NCT06120803` - Esomeprazole and Radiation Induced Esophagitis	Phase 2
Recruiting	`NCT06075524` - Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Recruiting	`NCT03735095` - Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer	Phase 1/Phase 2
Recruiting	`NCT04680377` - Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients